Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1388P - Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC)

Date

21 Oct 2023

Session

Poster session 20

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Shirish Gadgeel

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

S.M. Gadgeel1, Q. Zhang2, H. Lin3, O. Fajardo4, H. Trinh5, S. Arndorfer6, S. Kong7, A. Rahman8, S. Li9, V.R. Archer10, J.F. Gainor11

Author affiliations

  • 1 Department Of Internal Medicine, Henry Ford Cancer Institute/Henry Ford Health System, 48202 - Detroit/US
  • 2 Product Development Data Science, Genentech, Inc., 94080 - South San Francisco/US
  • 3 Roche Product Development Shanghai, Roche Holding Ltd, Shanghai/CN
  • 4 Product Development Data Sciences, F. Hoffmann-La Roche Ltd, 4070 - Basel/CH
  • 5 Product Development Real-world Data Science, Genentech, Inc., 94080 - South San Francisco/US
  • 6 Real-world Evidence, Genesis Research, 94080 - Hoboken/US
  • 7 Biostatistics, Genentech, Inc., 94080 - South San Francisco/US
  • 8 Product Development Clinical Development, Roche Products Ltd, AL7 1TW - Welwyn Garden City/GB
  • 9 Product Development Oncology, Genentech, Inc., 94080 - South San Francisco/US
  • 10 Pdc, Roche Products Ltd, AL7 1TW - Welwyn Garden City/GB
  • 11 Department Of Medicine, Center for Thoracic Cancers, Massachusetts General Hospital Cancer Center, 02114 - Boston/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1388P

Background

RET fusions are found in 1–2% of patients (pts) with NSCLC. RET inhibitors (RETi) have recently been approved for RET fusion-positive (RET+) aNSCLC, but the prognostic value of RET fusions is unclear. This study aimed to describe the overall survival (OS) of pts with RET+ or RET wild-type (RET-WT: no RET alterations) NSCLC using real-world data from two large databases.

Methods

This was a retrospective, observational study using US-based data from 1) a nationwide Flatiron Health–Foundation Medicine NSCLC clinico-genomic de-identified database (FH-FMI CGDB) and 2) a nationwide longitudinal electronic health record-derived FH de-identified database (FH). Pts with aNSCLC diagnosed between 1 Jan 2011 and 31 Dec 2021 (CGDB) or 30 Sep 2022 (FH) with known RET fusion status were included. Pts with other actionable gene alterations or previous treatment with RETi or a clinical study drug in any line were excluded. The primary objective was to compare the OS of pts with RET-WT vs RET+ aNSCLC in 1) all pts (index date: date of advanced diagnosis) and 2) pts who received first-line (1L) chemotherapy plus cancer immunotherapy (index date: start of 1L therapy). Hazard ratios (HRs) for left-truncated OS (to account for immortal time from index to RET testing) were adjusted for confounding variables using a multivariate Cox proportional regression model.

Results

Overall, 45 (CGDB) and 60 (FH) pts with RET+ aNSCLC, and 5,890 (CGDB) and 16,566 (FH) pts with RET-WT aNSCLC were included in the analysis. Pts with RET+ NSCLC tended to be younger (<65 yrs old: 51% vs 33%), less frequently smokers (8% vs 47%), and less commonly had KRAS (7% vs 34%) and TP53 (42% vs 72%) mutations than RET-WT pts. In CGDB and FH, there was no significant difference in OS between RET-WT and RET+ pts (Table).

Conclusions

Data from this real-world study using two large databases show that pts with RET+ aNSCLC do not have a different prognosis than pts with RET-WT aNSCLC. These data suggest that RET fusions have no prognostic value in aNSCLC. Table: 1388P

Pts with RET+ or RET-WT NSCLC from the CGDB Pts with RET+ or RET-WT NSCLC from the FH database
Cohort RET fusion status Events/N Median OS (95% CI) Adjusted HR (95% CI) Events (n/N) Median OS (95% CI) Adjusted HR (95% CI)
All pts* RET+ 25/45 12.0 (5.2–25.1) 1.08 (0.72–1.63) 33/60 12.9 (7.1–27.2) 1.28 (0.83–1.97)
RET-WT 4,101/5,890 7.9 (7.4–8.3) 10,958/16,566 8.7 (8.5–9.0)
1L chemotherapy + cancer immunotherapy RET+ 9/16 14.9 (10.6–NR) 0.93 (0.47–1.85) 6/14 7.0 (4.5–NR) 1.10 (0.49–2.45)
RET-WT 946/1,603 10.5 (9.5–11.1) 2,647/4,572 10.3 (9.8–10.9)

*Index: advanced diagnosis date; index: start of 1L therapy; adjusted by multivariate Cox proportional regression model for multiple covariates.

Clinical trial identification

Editorial acknowledgement

Medical writing support for the development of this abstract was provided by Lietta Nicolaides, PhD, and Laura Vergoz, PhD, of Ashfield MedComms, an Inizio company, and funded by F. Hoffmann-La Roche Ltd.

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd/Genentech, Inc.

Funding

F. Hoffmann-La Roche Ltd/Genentech Inc.

Disclosure

S.M. Gadgeel: Financial Interests, Personal, Advisory Board: Genentech/Roche, AstraZeneca, Mirati, Pfizer, Blueprint, Takeda, Bristol Myers Squibb, Merck, Eisai, Gilead, GSK, Arcus; Financial Interests, Personal, Other, Travel: Mirati. Q. Zhang: Financial Interests, Personal, Full or part-time Employment: Roche/Genentech; Financial Interests, Personal, Stocks/Shares: Roche, Regeneron, BMS, AbbVie, Pfizer, BioNTech, AC Immune. O. Fajardo: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche. H. Trinh: Financial Interests, Personal, Full or part-time Employment: Genentech, Inc; Financial Interests, Personal, Stocks/Shares: Roche. S. Kong: Financial Interests, Personal, Other, Former Employee: Roche; Financial Interests, Personal, Stocks/Shares: Roche. A. Rahman: Financial Interests, Personal, Stocks/Shares: Merck, Roche; Financial Interests, Personal, Full or part-time Employment: Roche. S. Li: Financial Interests, Personal, Full or part-time Employment: Genentech, Inc. V.R. Archer: Financial Interests, Personal, Full or part-time Employment: Roche; Financial Interests, Personal, Stocks/Shares: Roche. J.F. Gainor: Financial Interests, Personal, Advisory Board: AI Protein, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech/Roche, GlydeBio, iTeos, Karyopharm, Lilly, Merck, Mirati, Moderna, Novartis, Pfizer, Silverback Therapeutics, Takeda; Financial Interests, Personal, Stocks/Shares: Ironwood Pharmaceuticals; Non-Financial Interests, Institutional, Coordinating PI: Alexo, AstraZeneca, Bristol Myers Squibb, Genentech, Inc. Jounce, Merck, Moderna, Novartis; Financial Interests, Personal, Coordinating PI: Novartis; Financial Interests, Personal, Local PI: Scholar Rock and Palleon; Other, Personal, Full or part-time Employment, Immediate family member is an employee: Ironwood Pharmaceuticals. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.